Tardive Dyskinesia Latest Advances

Valbenazine Improves Quality of Life, Functionality, and Movement Severity in Patients With Tardive Dyskinesia: Findings From the KINECT-PRO™ Study.

Journal: CNS spectrums

Published: August 10, 2026

VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know.

Journal: Focus (American Psychiatric Publishing)

Published: August 01, 2026

Perceptions on the diagnosis and treatment of patients with tardive dyskinesia: a cross-sectional survey among physicians in Italy.

Journal: Rivista di psichiatria

Published: July 21, 2026

Silent action of dopamine receptor antagonist in synaptic remodelling: Molecular basis of tardive dyskinesia due to chronic antipsychotic exposure.

Journal: Progress in neuro-psychopharmacology & biological psychiatry

Published: June 29, 2026

Short-Course, Low-Dose Metoclopramide as Bridge Therapy for Dysautonomia-Associated Gastrointestinal Dysmotility in Adolescents: A Case Series.

Journal: Children (Basel, Switzerland)

Published: June 13, 2026

Is functional neurosurgery offering new hope for patients with hyperkinetic disorders? A mini-review of the current data on the use of DBS in hyperkinetic movement disorders.

Journal: Parkinsonism & related disorders

Published: June 01, 2026

Management of severe tardive dyskinesia induced by arpiprazole in a schizophrenic patient: a case report.

Journal: Journal of medical case reports

Published: May 31, 2026

Response to [Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia].

Journal: Psychiatry and clinical neurosciences

Published: May 30, 2026

Genetics of tardive dyskinesia: a review of progress over the past decade.

Journal: Pharmacogenomics

Published: May 18, 2026

Clinical and neurobiological correlates of tardive dyskinesia in schizophrenia spectrum disorders and mood disorders.

Journal: Schizophrenia (Heidelberg, Germany)

Published: May 12, 2026

Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia.

Journal: Psychiatry and clinical neurosciences

Published: May 09, 2026

Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials.

Journal: The Journal of clinical psychiatry

Published: May 07, 2026

Tardive Dyskinesia Latest Advances

Find the Latest Research About Tardive Dyskinesia

Valbenazine Improves Quality of Life, Functionality, and Movement Severity in Patients With Tardive Dyskinesia: Findings From the KINECT-PRO™ Study.

Valbenazine Improves Quality of Life, Functionality, and Movement Severity in Patients With Tardive Dyskinesia: Findings From the KINECT-PRO™ Study.

VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know.

VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know.

Perceptions on the diagnosis and treatment of patients with tardive dyskinesia: a cross-sectional survey among physicians in Italy.

Perceptions on the diagnosis and treatment of patients with tardive dyskinesia: a cross-sectional survey among physicians in Italy.

Silent action of dopamine receptor antagonist in synaptic remodelling: Molecular basis of tardive dyskinesia due to chronic antipsychotic exposure.

Silent action of dopamine receptor antagonist in synaptic remodelling: Molecular basis of tardive dyskinesia due to chronic antipsychotic exposure.

Short-Course, Low-Dose Metoclopramide as Bridge Therapy for Dysautonomia-Associated Gastrointestinal Dysmotility in Adolescents: A Case Series.

Short-Course, Low-Dose Metoclopramide as Bridge Therapy for Dysautonomia-Associated Gastrointestinal Dysmotility in Adolescents: A Case Series.

Is functional neurosurgery offering new hope for patients with hyperkinetic disorders? A mini-review of the current data on the use of DBS in hyperkinetic movement disorders.

Is functional neurosurgery offering new hope for patients with hyperkinetic disorders? A mini-review of the current data on the use of DBS in hyperkinetic movement disorders.

Management of severe tardive dyskinesia induced by arpiprazole in a schizophrenic patient: a case report.

Management of severe tardive dyskinesia induced by arpiprazole in a schizophrenic patient: a case report.

Response to [Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia].

Response to [Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia].

Genetics of tardive dyskinesia: a review of progress over the past decade.

Genetics of tardive dyskinesia: a review of progress over the past decade.

Clinical and neurobiological correlates of tardive dyskinesia in schizophrenia spectrum disorders and mood disorders.

Clinical and neurobiological correlates of tardive dyskinesia in schizophrenia spectrum disorders and mood disorders.

Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia.

Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia.

Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials.

Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials.